Vaxcyte Net Debt from 2010 to 2024
| PCVX Stock | USD 112.94 0.62 0.55% |
Net Debt | First Reported 2010-12-31 | Previous Quarter -368.2 M | Current Value -386.6 M | Quarterly Volatility 219.5 M |
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
Vaxcyte | Net Debt |
Latest Vaxcyte's Net Debt Growth Pattern
Below is the plot of the Net Debt of Vaxcyte over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Vaxcyte's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Vaxcyte Net Debt Regression Statistics
| Arithmetic Mean | (177,299,090) | |
| Coefficient Of Variation | (123.82) | |
| Mean Deviation | 166,477,999 | |
| Median | (65,632,000) | |
| Standard Deviation | 219,526,045 | |
| Sample Variance | 48191.7T | |
| Range | 764.5M | |
| R-Value | (0.63) | |
| Mean Square Error | 31045.5T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (31,115,659) | |
| Total Sum of Squares | 674683.6T |
Vaxcyte Net Debt History
Other Fundumenentals of Vaxcyte
Vaxcyte Net Debt component correlations
Click cells to compare fundamentals
About Vaxcyte Financial Statements
Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt | -368.2 M | -386.6 M | |
| Net Debt To EBITDA | 0.79 | 0.75 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| V | Visa Class A | |
| MSFT | Microsoft |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.